RxDoctor Payments DataLook up a doctor →

Matthew Ostrom, MD

Clinical Cardiac Electrophysiology · Torrance, CANPI 1205033073

Payments from drug & device makers

$238,425in general payments, 2019–2025

Across 1,016 payments — averaging $234.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$152K
  • Cvrx, Inc.$36K
  • Medtronic$32K
  • Abbott$9K
  • Sanofi-aventis U.S. LLC$3K
  • Novartis$725
  • plus $6K from 40 others

What the payments were for

  • Consulting fees$10,11917%
  • Speaking & faculty fees$14,76424%
  • Travel & lodging$3,6016%
  • Food & beverage$32,55053%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$238,425 in reported general payments places this provider in the 80th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California

Medicare billing

Part B allowed, 2024
$463,527
Medicare patients
1,300
Services billed
7,922

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,075$1,271,687
XareltoRivaroxaban280$381,598
EntrestoSacubitril/Valsartan134$168,122
MultaqDronedarone Hcl45$78,089
JardianceEmpagliflozin51$65,267
FarxigaDapagliflozin Propanediol26$23,599
Praluent PenAlirocumab17$11,091
Diltiazem 24hr Er (Cd)Diltiazem Hcl172$10,735
Betapace AfSotalol Hcl13$10,200
Metoprolol Succinate449$9,309
Flecainide Acetate160$9,182
Amiodarone Hcl146$5,231
SotalolSotalol Hcl177$3,772
Atorvastatin Calcium293$3,375
Rosuvastatin Calcium207$2,765

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$582$1,271,6871,075 claims
Johnson & JohnsonXarelto$546$381,598280 claims
NovartisEntresto$725$168,122134 claims
Sanofi-aventis U.S. LLCMultaq$2,844$78,08945 claims
Boehringer IngelheimJardiance$120$65,26751 claims
AstraZenecaFarxiga$225$23,59926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 290 clinical cardiac electrophysiology providers in California.

Other clinical cardiac electrophysiology in Torrance

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →